Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

The Evolution of Chronic Hives Treatment: Moving Beyond Antihistamines

For millions of people living with chronic spontaneous urticaria (CSU), the daily reality is a cycle of unpredictable flares, debilitating itch, and swelling. While H1-antihistamines have long been the first line of defense, they aren’t a universal solution. In fact, more than 50% of patients continue to experience severe symptoms even after conventional antihistamine therapy.

The landscape is shifting toward targeted oral therapies. The emergence of highly selective BTK inhibitors represents a pivotal change in how we approach immune-mediated skin conditions, moving from merely suppressing symptoms to blocking the pathways that cause them.

Breaking the Cycle of Ineffective Treatment

CSU is more than just a skin irritation; it is a systemic issue that impacts emotional wellbeing, sleep, and overall productivity. When standard antihistamines fail, patients often face a gap in care that leaves them vulnerable to sudden hives (wheals) and deep tissue swelling (angioedema) on the face, throat, hands, and feet.

The trend is now moving toward “targeted” approaches. Rather than a broad-spectrum response, new therapies like Rhapsido (remibrutinib) focus on the specific immune drivers of the disease. This allows for a more precise intervention for those who remain symptomatic after initial treatments.

The Science of BTK Inhibition: A New Frontier

At the heart of this medical advancement is the inhibition of Bruton’s Tyrosine Kinase (BTK). BTK is a key enzyme involved in the release of histamine—the primary driver of the itchy hives and swelling associated with CSU.

By utilizing a highly selective oral BTK inhibitor, the treatment blocks the pathway that triggers histamine release. This mechanism offers a distinct advantage: it addresses the root of the inflammatory response rather than just treating the resulting itch.

Rapid Relief and Safety Profiles

One of the most significant trends in new immunology drugs is the demand for speed. Clinical data from the REMIX-1 and REMIX-2 studies—which involved 925 patients—showed significant improvements in itch and hives as early as Week 1.

the industry is moving toward “low-burden” treatments. Unlike some systemic therapies that require frequent blood work or liver function tests, remibrutinib has demonstrated a safety profile that requires no lab monitoring. Common side effects are generally mild, including nasopharyngitis (nasal congestion, sore throat, and runny nose), headache, and nausea.

Redefining the Patient Experience in Immunology

The shift toward oral administration is a major win for patient adherence. A pill taken twice daily is far less invasive than injectable biologics, removing the barrier of clinic visits for administration.

This trend toward patient-centric design is likely to expand. When a treatment offers both efficacy and convenience—without the need for constant lab monitoring—it transforms the disease management process from a medical burden into a manageable part of a daily routine.

Expanding the Horizon: Beyond CSU

The success of the BTK pathway in treating CSU is opening doors for other immune-mediated conditions. We are seeing a trend where a single targeted approach is being investigated for a variety of inflammatory diseases.

Current research is exploring the potential of remibrutinib for several other indications, including:

• Chronic Inducible Urticaria (CIndU): Showing positive topline results across the three most prevalent subtypes in Phase III trials.
• Food Allergies: Investigating the ability to block allergic reactions.
• Hidradenitis Suppurativa (HS): Addressing severe inflammatory skin nodules.
• Neuroscience: Exploring the BTK pathway’s role in neurological health.

For more information on how these therapies are changing the standard of care, you can explore the Novartis official site or read our other guides on immune-mediated skin disorders.

Frequently Asked Questions